Intellia Therapeutics (NASDAQ:NTLA) Downgraded by Zacks Investment Research to Sell

Share on StockTwits

Zacks Investment Research downgraded shares of Intellia Therapeutics (NASDAQ:NTLA) from a hold rating to a sell rating in a research report released on Tuesday, Zacks.com reports.

According to Zacks, “Intellia Therapeutics is a leading genome editing company, focused on developing therapeutics utilizing a biological tool known as CRISPR-Cas9 system. It believes the CRISPR-Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company’s sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. Intellia’s combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts it in a unique position to unlock broad therapeutic applications of the CRISPR-Cas9 technology and create a new class of therapeutic products. “

Several other analysts have also recently commented on NTLA. BidaskClub upgraded shares of Intellia Therapeutics from a sell rating to a hold rating in a research report on Thursday, February 6th. Raymond James upgraded shares of Intellia Therapeutics from a market perform rating to an outperform rating and set a $24.00 price objective for the company in a research report on Friday, November 1st. Chardan Capital restated a buy rating and issued a $57.50 price objective on shares of Intellia Therapeutics in a research report on Monday, February 10th. Finally, ValuEngine cut shares of Intellia Therapeutics from a buy rating to a hold rating in a research report on Tuesday, November 5th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company. The stock currently has a consensus rating of Hold and an average target price of $25.25.

Shares of Intellia Therapeutics stock opened at $13.86 on Tuesday. The firm has a fifty day moving average of $14.27 and a two-hundred day moving average of $14.54. The stock has a market capitalization of $677.51 million, a price-to-earnings ratio of -7.04 and a beta of 2.82. Intellia Therapeutics has a 52 week low of $10.26 and a 52 week high of $19.00. The company has a debt-to-equity ratio of 0.05, a quick ratio of 7.89 and a current ratio of 7.89.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Great West Life Assurance Co. Can bought a new stake in shares of Intellia Therapeutics in the 4th quarter valued at $35,000. Wealthcare Advisory Partners LLC acquired a new position in Intellia Therapeutics in the 4th quarter worth $37,000. Exchange Traded Concepts LLC acquired a new position in Intellia Therapeutics in the 4th quarter worth $56,000. Bank of Montreal Can boosted its stake in Intellia Therapeutics by 32.8% in the 4th quarter. Bank of Montreal Can now owns 5,258 shares of the company’s stock worth $77,000 after purchasing an additional 1,300 shares during the period. Finally, Victory Capital Management Inc. boosted its stake in Intellia Therapeutics by 69.6% in the 4th quarter. Victory Capital Management Inc. now owns 8,514 shares of the company’s stock worth $125,000 after purchasing an additional 3,493 shares during the period. Institutional investors and hedge funds own 90.10% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria.

Recommended Story: What member countries make up the G-20?

Get a free copy of the Zacks research report on Intellia Therapeutics (NTLA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Microsoft Co.  Shares Sold by North Star Asset Management Inc.
Microsoft Co. Shares Sold by North Star Asset Management Inc.
Point View Wealth Management Inc. Lowers Stock Position in Microsoft Co.
Point View Wealth Management Inc. Lowers Stock Position in Microsoft Co.
Secure Asset Management LLC Acquires New Holdings in Microsoft Co.
Secure Asset Management LLC Acquires New Holdings in Microsoft Co.
Microsoft Co.  Stake Increased by Wedgewood Investors Inc. PA
Microsoft Co. Stake Increased by Wedgewood Investors Inc. PA
Palladium Partners LLC Has $59.59 Million Stock Holdings in Microsoft Co.
Palladium Partners LLC Has $59.59 Million Stock Holdings in Microsoft Co.
State of Tennessee Treasury Department Sells 82,917 Shares of Microsoft Co.
State of Tennessee Treasury Department Sells 82,917 Shares of Microsoft Co.


 
© 2006-2020 Zolmax.